Twice-Yearly HIV Prevention Injection Approved by FDA | UNC-Chapel Hill
7 Articles
7 Articles
Twice-yearly HIV prevention injection approved by FDA | UNC-Chapel Hill
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, in June. The injection, which boasts a six-month-long period of effective protection, will help mitigate health care access gaps and prevent further infections brought on by low medication adherence. Dr. Joe Eron, the Herman and Louise Smith Distinguished Professor of Medicine and director of the clinical core at the UNC Center for AIDS Resear…
The World Health Organization (WHO) recommended Gilead Lenacapavir , an injection given twice a year as a tool to prevent HIV infection. How effective is the drug? Is it available outside the United States? Side Effects The recommendation, issued at the International AIDS Conference in Kigali, Rwanda occurs almost a month after the U.S. health authority approves the drug, giving patients new hopes to stop transmission of the virus.

The Director General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, reported on Wednesday that WHO and its partners are working with nine countries so that nearly two million people can access Lenacapavir injection - a drug for HIV prevention - at a lower negotiated price.
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, reported on Wednesday that WHO and its partners are working with nine countries so that nearly two million people can access lenacapavir injection - a drug for HIV prevention - at a lower negotiated price.
Updated HIV guidelines from WHO promote prevention and lower barriers to care
New guidelines recommended by WHO will need to be backed with funding to be implemented at scale in affected communities.The post Updated HIV guidelines from WHO promote prevention and lower barriers to care appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium